<DOC>
	<DOCNO>NCT01874951</DOCNO>
	<brief_summary>The purpose pilot study determine take low dose naltrexone addition antidepressant medication help treat relapse recurrence people Major Depressive Disorder ( MDD ) . The U.S. Food Drug Administration ( FDA ) approve naltrexone treatment alcohol dependence opioid dependence , FDA approve naltrexone treat depression . The investigator hypothesize patient breakthrough depression antidepressant regimen contain pro-dopaminergic agent assign treatment low dose naltrexone demonstrate high rate response compare patient take placebo .</brief_summary>
	<brief_title>Low-Dose Naltrexone ( LDN ) Depression Relapse Recurrence</brief_title>
	<detailed_description>We carry pilot double-blind , randomize , control study low-dose naltrexone ( LDN ) 1 mg b.i.d . versus placebo augmentation MDD patient relapse dopaminergic agent . The primary aim test hypothesis patient experience depressive breakthrough would demonstrate great improvement depression supplement current antidepressant regimen LDN versus placebo , significant difference side effect . Boston area men woman MDD recruit 01/13/2014-11/11/2014 via Institutional Review Board ( IRB ) -approved newspaper , television , internet , radio ad initiate Massachusetts General Hospital ( MGH ) Boston Clinical Trials ( BCT ) . Screened eligible patient return one week later baseline visit randomize consecutively double-blind treatment placebo LDN 1 mg b.i.d . The randomization list generate online randomization program maintain research pharmacist . Subjects treat 3 week , weekly assessment . All subject require continue baseline antidepressant regimen without change duration study ; likewise ask modify allow baseline medication take prior enter study . Adherence determine weekly pill count ; protocol violation define less 80 % adherence . Side effect assess every visit use Systematic Assessment Treatment Emergent Effects-Specific Inquiry ( SAFTEE-SI ) scale ( Levine Schooler , 1992 ) categorize severity : 0-none , 1-mild , 2-moderate , 3-severe . Because SAFTEE item could present baseline , particularly sample subject take antidepressant could produce side effect , define treatment-emergent SAFTEE side effect severity increase two level ( e.g . none moderate mild severe ) baseline ( Mischoulon et al. , 2014 ) . Frequency side effect base number patient report side effect time study . Suicidal ideation assess visit use Hamilton Depression Rating Scale ( HAM-D ) . Subjects consider high risk suicide discontinue referred evaluation hospitalization clinically indicate . Subjects also discontinue emergence hypomania , mania , psychosis ; Clinical Global Improvement ( CGI-I ) score great 5 ( e.g. , score 6 7 ) ; evidence illicit drug use problematic alcohol use . At end double-blind study , responder non-responders complete double-blind phase option receive open-label adjunctive treatment LDN 3 week . Paired independent sample t-tests nonparametric counterpart ( Wilcoxon 's signed rank Mann-Whitney U test ) use examine compare outcomes treatment arm . All analyse two-tailed . Response remission rate , emergence side effect compare Fisher 's exact test . Effect size ( ES ) calculate Cohen 's ( Cohen , 1988 ) , between-subjects comparison ( change depression scale baseline end LDN vs. placebo ) within-subjects comparison ( change depression scale baseline end separate treatment group ) . Correlation coefficient calculate use within-subjects comparison . Statistical analysis carry use SPSS version 17.0 ( SPSS Inc , Chicago , Illinois ) .</detailed_description>
	<mesh_term>Depression</mesh_term>
	<mesh_term>Depressive Disorder</mesh_term>
	<mesh_term>Recurrence</mesh_term>
	<mesh_term>Depressive Disorder , Major</mesh_term>
	<mesh_term>Antidepressive Agents</mesh_term>
	<mesh_term>Naltrexone</mesh_term>
	<criteria>Age 1865 . Written informed consent . Meet Diagnostic Statistical Manual ( DSMIV ) criterion Structured Clinical Interview DSMIV ( SCIDI/P ) Major Depressive Disorder ( MDD ) , current . Quick Inventory Depressive Symptomatology SelfRated ( QIDSSR ) score least 12 screen baseline visit . Received treatment either Selective serotonin reuptake inhibitor ( SSRI ) combination dopaminergic agent , antidepressant dopaminergic mechanism action adequate dos , achieve remission per American College Neuropsychopharmacology ( ACNP ) Task Force guideline â‰¥3 month , currently relapse recurrence without dose change least past 4 week , base meeting DSMIV criterion MDD . 1 . Dopaminergic agent include classical stimulant amphetamine methylphenidate family ; dopamine agonist ( e.g . pramipexole ) ; dopamine active antidepressant like bupropion . 2 . Additionally , low dose ( &lt; 2.5 mg ) Abilify , D2 partial agonist , believe exert prodopaminergic effect therefore include dopamine agent . 3 . Sertraline , although classified SSRI , dopamine reuptake inhibit property believe relevant high dos ( &gt; 150 mg sertraline ) , also therefore consider dopaminergic antidepressant dose range . 4 . Based find norepinephrine transporter reuptake inhibitor dopamine prefrontal cortex robust sustain clinical response patient duloxetine low dose naltrexone , include duloxetine , traditionally class SNRI , among dopamine act antidepressant . ) During baseline visit , patient must stable dose antidepressant regimen past 4 week . Pregnant woman woman child bear potential use medically accept mean contraception ( include oral contraceptive implant , condom , diaphragm , spermicide , intrauterine device , tubal ligation , partner vasectomy ) . Patients longer meet DSMIV criterion MDD baseline visit . Patients demonstrate great 25 % decrease depressive symptom reflect QIDSSR total score screen baseline . Serious suicide homicide risk , assess evaluate clinician . Unstable medical illness include cardiovascular , hepatic , renal , respiratory , endocrine , neurological , hematological disease . Substance use disorder active within last six month , bipolar disorder ( current past ) , psychotic disorder ( current past ) . History seizure disorder clinical evidence untreated hypothyroidism . Patients require excluded medication ( include limit chronic episodic use anorexiants , episodic hormone , episodic benzodiazepine , episodic insulin , episodic episodic psychotropic medication ) . Psychotic feature current episode history psychotic feature , assess SCID . History naltrexone intolerance dose . Patients history antidepressantinduced hypomania . Inadequate exposure time dose current SSRI Serotoninnorepinephrine reuptake inhibitor ( SNRI ) ; failure comply least 80 % dos .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>Depression</keyword>
	<keyword>Recurrence</keyword>
	<keyword>Relapse</keyword>
	<keyword>Antidepressants</keyword>
	<keyword>Naltrexone</keyword>
	<keyword>Drug augmentation</keyword>
</DOC>